Gf Fund Management Co., Ltd. - CSI Hong Kong Brand Name Drug Index ETF (SHA:513120)
China · Delayed Price · Currency is CNY 1.281
+0.009 (0.71%)
At close: Apr 14, 2026
49.47% (1Y)
| Assets | n/a |
| Expense Ratio | n/a |
| PE Ratio | 24.57 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +48.43% |
| Volume | 3,828,123,713 |
| Open | 1.281 |
| Previous Close | 1.272 |
| Day's Range | 1.263 - 1.287 |
| 52-Week Low | 0.842 |
| 52-Week High | 1.629 |
| Beta | 0.87 |
| Holdings | 40 |
| Inception Date | Jul 1, 2022 |
About 513120
513120.SS was created on 2022-07-01 by GF Fund. The fund's investment portfolio concentrates primarily on health care equity. Tightly track the target index, pursue the minimization of tracking deviation and tracking error. The fund strives to control the absolute value of the daily average tracking deviation between the net value growth rate of the investment portfolio & the performance benchmark is less than 0.2%, & the annualized tracking deviation is less than 0.2%.
Asset Class Equity
Category Health Care
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 513120
Provider GF Fund
Index Tracked CSI Hong Kong Innovative Drug Index - CNY - Benchmark TR Gross
Performance
513120 had a total return of 48.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.72%.
Top 10 Holdings
69.92% of assets| Name | Symbol | Weight |
|---|---|---|
| BeOne Medicines AG | 6160 | 9.97% |
| Innovent Biologics, Inc. | 1801 | 9.61% |
| Akeso, Inc. | 9926 | 8.40% |
| WuXi Biologics (Cayman) Inc. | 2269 | 8.22% |
| Sino Biopharmaceutical Limited | 1177 | 7.04% |
| CSPC Pharmaceutical Group Limited | 1093 | 6.87% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 6.55% |
| WuXi AppTec Co., Ltd. | 2359 | 5.09% |
| 3SBio Inc. | 1530 | 4.94% |
| XtalPi Holdings Limited | 2228 | 3.23% |